| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg | |||
| Other Sizes |
| Targets |
Liriope muscari baily saponins C targets multiple pathways involved in inflammation, immunity, and thrombosis. It has anti-thrombotic activity due to down-regulation of the increased mRNA expression levels of IL-6 and TF (tissue factor). Its anti-inflammatory and immunopharmacological effects suggest modulation of immune cell function and inflammatory mediators. Its cardioprotective effects indicate protection of cardiac tissue. The compound's ability to induce autophagy suggests effects on cellular homeostasis and survival. Its potential as a tumor metastasis candidate indicates effects on cancer cell migration and invasion.
|
|---|---|
| ln Vitro |
In vitro, Liriope muscari baily saponins C has demonstrated anti-inflammatory, immunopharmacological, and cardioprotective activities. It induces autophagy. It has anti-thrombotic activity due to down-regulation of IL-6 and TF mRNA expression. Its effects on cancer cell metastasis have been investigated. These activities confirm its potential for research on inflammation, immune disorders, cardiovascular diseases, and cancer. Detailed in vitro studies are described in the primary literature.
|
| ln Vivo |
In vivo, Liriope muscari baily saponins C has been studied for its anti-thrombotic, anti-inflammatory, and cardioprotective effects. Its anti-thrombotic activity has been demonstrated in animal models. Its cardioprotective effects suggest potential for treating cardiovascular diseases. Its anti-inflammatory and immunopharmacological effects have been studied in various disease models. Its potential as a tumor metastasis candidate suggests it may inhibit cancer spread in vivo. Detailed in vivo studies are described in the primary literature.
|
| Enzyme Assay |
For in vitro biochemical assays, Liriope muscari baily saponins C is evaluated for its anti-inflammatory, anti-thrombotic, and immunomodulatory activities. IL-6 and TF mRNA expression is measured by qPCR in treated cells. Autophagy induction is assessed by measuring LC3-II conversion and p62 levels by Western blotting. Anti-inflammatory activity is assessed by measuring cytokine production using ELISA. Immunomodulatory effects are assessed by measuring immune cell proliferation and activation. These cell-free and cell-based assays help characterize the compound's multiple biological activities.
|
| Cell Assay |
In vitro cellular assays for Liriope muscari baily saponins C are performed using various cell types including immune cells, endothelial cells, and cancer cells. Cells are cultured in standard media and treated with the compound at various concentrations. IL-6 and TF expression is measured by qPCR or ELISA. Autophagy is assessed by measuring LC3-II conversion and p62 levels. Anti-inflammatory activity is assessed by measuring cytokine production. Immunomodulatory effects are assessed by measuring immune cell function. Anticancer activity is assessed using cell viability, proliferation, migration, and invasion assays. These cellular assays help validate the compound's anti-inflammatory, anti-thrombotic, immunomodulatory, and anticancer activities.
|
| Animal Protocol |
In vivo animal experiments with Liriope muscari baily saponins C are conducted in models of thrombosis, inflammation, and cancer. For thrombosis studies, animal models of venous or arterial thrombosis are used. For anti-inflammatory studies, models of acute or chronic inflammation are used. For cardioprotective studies, models of cardiac injury are used. For cancer studies, tumor metastasis models are employed. The compound is administered via oral gavage, intraperitoneal injection, or intravenous injection. Efficacy endpoints include thrombus formation, inflammation markers, cardiac function, and tumor metastasis.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Liriope muscari baily saponins C have been partially characterized. As a steroidal saponin with a molecular weight of 855.02, it is expected to have limited oral bioavailability due to its large molecular size and glycosidic structure. The compound may be metabolized by intestinal microbiota. Detailed PK parameters such as half-life, Cmax, Tmax, AUC, and protein binding are not extensively documented. The compound should be stored under recommended conditions to maintain stability.
|
| Toxicity/Toxicokinetics |
The toxicological profile of Liriope muscari baily saponins C is not extensively characterized. As a natural steroidal saponin from Liriope muscari, it is generally considered to have a moderate safety profile, but comprehensive toxicity studies are limited. The compound is intended for research use only and not for human therapeutic applications. Its effects at high concentrations and potential interactions with other drugs or compounds have not been fully investigated. Researchers should follow standard laboratory safety practices when handling this compound.
|
| References | |
| Additional Infomation |
Liriope muscari baily saponins C is a valuable research tool for studying anti-inflammatory, immunomodulatory, cardioprotective, and anti-thrombotic mechanisms. Its ability to down-regulate IL-6 and TF expression makes it useful for investigating the role of these mediators in thrombosis and inflammation. Its autophagy-inducing activity provides opportunities for studying autophagy regulation. Its potential as a tumor metastasis candidate makes it relevant for cancer research. As a major active component of Liriope muscari, it is also important for natural product chemistry and the quality control of herbal medicines.
|
| Molecular Formula |
C44H70O16
|
|---|---|
| Molecular Weight |
855.0170
|
| Exact Mass |
854.466
|
| CAS # |
87480-46-4
|
| PubChem CID |
14682468
|
| Appearance |
White to light yellow solid
|
| Density |
1.4±0.1 g/cm3
|
| Index of Refraction |
1.618
|
| LogP |
6.69
|
| Hydrogen Bond Donor Count |
8
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
60
|
| Complexity |
1570
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C[C@]12CC[C@@H]3[C@]4(CC[C@H](O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O[C@@H]6OC[C@@H](O)[C@H](O)[C@H]6O)[C@H]5O[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)CC4=CC[C@H]3[C@@H]1C[C@@H]1O[C@@]3(OC[C@@H](C)CC3)[C@H]([C@H]21)C)C
|
| InChi Key |
DQYACEDUQHWXQZ-YZBXVEJJSA-N
|
| InChi Code |
InChI=1S/C44H70O16/c1-19-8-13-44(54-17-19)20(2)30-28(60-44)15-26-24-7-6-22-14-23(9-11-42(22,4)25(24)10-12-43(26,30)5)56-41-38(59-40-36(52)34(50)31(47)21(3)55-40)37(33(49)29(16-45)57-41)58-39-35(51)32(48)27(46)18-53-39/h6,19-21,23-41,45-52H,7-18H2,1-5H3/t19-,20-,21-,23-,24+,25-,26-,27+,28-,29+,30-,31-,32-,33+,34+,35+,36+,37-,38+,39-,40-,41+,42-,43-,44+/m0/s1
|
| Chemical Name |
(2S,3R,4R,5R,6S)-2-[(2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-2-[(1S,2S,4S,5'S,6R,7S,8R,9S,12S,13R,16S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxane]-16-yl]oxy-4-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-3-yl]oxy-6-methyloxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1696 mL | 5.8478 mL | 11.6956 mL | |
| 5 mM | 0.2339 mL | 1.1696 mL | 2.3391 mL | |
| 10 mM | 0.1170 mL | 0.5848 mL | 1.1696 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
